Cureus | Alpelisib-Induced Diabetic Ketoacidosis
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study - The Lancet Oncology
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer - ScienceDirect
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Positive Quality Intervention: Management of Alpelisib (Piqray®) Induced Hyperglycemia Description: This PQI is intended to add
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Nature Cancer
Considerations for Management of Alpelisib Induced Hyperglycemia
14 days Ambulatory Glucose Profile following start of alpelisib... | Download Scientific Diagram
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series - Tahj Blow, Parker N. Hyde, John N. Falcone, Aaron Neinstein, Neil Vasan, Ritika Chitkara, Maurice
Detecting and Managing Drug-Induced Diabetes
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report | Clinical Diabetes and Endocrinology | Full Text
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series - Tahj Blow, Parker N. Hyde, John N. Falcone, Aaron Neinstein, Neil Vasan, Ritika Chitkara, Maurice
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Novartis: US-Zulassung für Alpelisib | APOTHEKE ADHOC
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Alpelisib als neue Therapieoption bei Hormonrezeptor-positivem, HER2-negativem Brustkrebs - 10 - 2020 - Heftarchiv - AMT
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Pa | TCRM
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors - Ando - 2019 - Cancer Science - Wiley Online Library
Pharmacist Management of Alpelisib-Associated Hyperglycemia
Mechanism of Action | PIQRAY® (alpelisib) tablets | HCP
